Biomarkers are used across all stages of drug development, ranging from enrichment, stratification, and patient selection to safety, efficacy, and performance assessment
Our biomarker for out-licensing
| DPP3 biomarker guides doctors to act on the right information at the right time in intensive care units. |
| It is available for out-licensing to global In-Vitro Diagnostics and pharmaceutical companies. |
6 Patent families covering the use of DPP3 biomarker for various medical purposes
The DPP3 biomarker has been out-licensed to SphingoTec GmbH to be measured using Nexus IB10 Point of care.
Adrenomed AG evaluted DPP3 plasma levels in a prespecified analysis in the phase II trial and will use DPP3 for a planned phase III trial as an exclusion criterion for the patient selection
